JP2014520153A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520153A5
JP2014520153A5 JP2014517111A JP2014517111A JP2014520153A5 JP 2014520153 A5 JP2014520153 A5 JP 2014520153A5 JP 2014517111 A JP2014517111 A JP 2014517111A JP 2014517111 A JP2014517111 A JP 2014517111A JP 2014520153 A5 JP2014520153 A5 JP 2014520153A5
Authority
JP
Japan
Prior art keywords
pyrrolo
fluoro
pyridin
amino
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517111A
Other languages
English (en)
Japanese (ja)
Other versions
JP6026525B2 (ja
JP2014520153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/043276 external-priority patent/WO2012177714A1/en
Publication of JP2014520153A publication Critical patent/JP2014520153A/ja
Publication of JP2014520153A5 publication Critical patent/JP2014520153A5/ja
Application granted granted Critical
Publication of JP6026525B2 publication Critical patent/JP6026525B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517111A 2011-06-22 2012-06-20 置換６−アザ−イソインドリン−１−オン誘導体 Expired - Fee Related JP6026525B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500094P 2011-06-22 2011-06-22
US61/500,094 2011-06-22
PCT/US2012/043276 WO2012177714A1 (en) 2011-06-22 2012-06-20 Substituted 6-aza-isoindolin-1-one derivatives

Publications (3)

Publication Number Publication Date
JP2014520153A JP2014520153A (ja) 2014-08-21
JP2014520153A5 true JP2014520153A5 (enExample) 2015-08-06
JP6026525B2 JP6026525B2 (ja) 2016-11-16

Family

ID=46551850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517111A Expired - Fee Related JP6026525B2 (ja) 2011-06-22 2012-06-20 置換６−アザ−イソインドリン−１−オン誘導体

Country Status (4)

Country Link
US (3) US9056873B2 (enExample)
EP (1) EP2723739B1 (enExample)
JP (1) JP6026525B2 (enExample)
WO (1) WO2012177714A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010333804B2 (en) 2009-12-23 2015-07-16 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
CN103833665B (zh) * 2014-02-24 2015-09-23 杰达维（上海）医药科技发展有限公司 一种新的合成异噻唑的方法
GEP20197050B (en) 2014-12-18 2019-12-10 Pharmaceutical Company Limited Takeda Solid state forms of fused heteroaromatic pyrrolidinones
CA3077238C (en) 2017-09-28 2022-04-12 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
CN112384511B (zh) 2018-05-10 2024-01-30 硕腾服务有限责任公司 内寄生虫缩肽
CN111004211B (zh) * 2019-12-29 2021-04-02 苏州诚和医药化学有限公司 一种依匹哌唑中间体4-溴苯并［b］噻吩的合成方法
CN111393349A (zh) * 2020-05-15 2020-07-10 上海毕得医药科技有限公司 一种4-碘-1h-吡咯-2-甲醛的合成方法
CN117510431A (zh) * 2023-11-08 2024-02-06 浙江雅辰药物科技股份有限公司 一种异噻唑-3-酮及其衍生物、合成方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107966A (ja) 1986-05-22 1988-05-12 Fujisawa Pharmaceut Co Ltd ピリミジン誘導体
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE69839735D1 (de) 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
AU2095099A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
US6797706B1 (en) 1999-06-09 2004-09-28 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclecarboxamide derivative
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
EP1250128A2 (en) 1999-12-16 2002-10-23 Alcon, Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
CA2398956A1 (en) 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1546117A2 (en) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
EP1610793A2 (en) 2003-03-25 2006-01-04 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
DE602004014117D1 (de) 2003-03-25 2008-07-10 Vertex Pharma Thiazole zur verwendung als inhibitoren von protein-kinasen
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US8057815B2 (en) 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
WO2006028833A1 (en) 2004-09-01 2006-03-16 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2006108107A1 (en) 2005-04-06 2006-10-12 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
AU2006237920A1 (en) 2005-04-19 2006-10-26 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
CA2608476A1 (en) 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
AR056191A1 (es) 2005-08-23 2007-09-26 Idenix Phatmaceuticals Inc Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
CA2627242A1 (en) 2005-10-31 2007-05-10 Rigel Pharmaceuticals, Inc. Compositions and methods for treating inflammatory disorders
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
AR060316A1 (es) 2006-01-17 2008-06-11 Vertex Pharma Azaindoles de utilidad como inhibidores de janus quinasas
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
JPWO2008047831A1 (ja) 2006-10-17 2010-02-25 協和発酵キリン株式会社 Ｊａｋ阻害剤
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2420505A1 (en) 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
CA2673965A1 (en) 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Pyrazolopyrimidine compound
MX2009010207A (es) 2007-03-23 2009-10-19 Schering Corp Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
EP2162136A4 (en) 2007-06-03 2012-02-15 Univ Vanderbilt GLUTAMATE METABOTROPIC POSITIVE RECEPTOR-BASED ALLOSTERIC-MODULATOR BENZAMIDE DERIVATIVES (MGLUR5) AND METHODS OF MAKING AND USING THEM
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
JP2009067729A (ja) 2007-09-14 2009-04-02 Kyowa Hakko Kirin Co Ltd Ｈｓｐ９０ファミリー蛋白質阻害剤
AU2008323694A1 (en) 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
EP2252617A1 (en) 2008-02-13 2010-11-24 CGI Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
LT2252300T (lt) 2008-02-22 2017-02-10 Rigel Pharmaceuticals, Inc. 2,4-pirimidindiaminų panaudojimas aterosklerozės gydymui
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
EP2321283B1 (en) 2008-04-16 2016-07-13 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
CA2728893C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
KR20110031318A (ko) 2008-06-13 2011-03-25 노파르티스 아게 Ｉａ 심부전 및 암 치료에 유용한 단백질 키나제 ｄ 억제제로서의 2,4'-비피리디닐 화합물
EP2324022A1 (de) 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
CA2731926A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
EA021293B1 (ru) 2008-12-08 2015-05-29 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20120172384A1 (en) 2009-06-18 2012-07-05 Mihiro Sunose Heterocyclylaminopyrimidines as kinase inhibitors
MA33926B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
WO2011075560A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
AU2010333804B2 (en) 2009-12-23 2015-07-16 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2014520153A5 (enExample)
AU2022200741B2 (en) Aminothiazole compounds as c-Kit inhibitors
AU2022201082B2 (en) Benzimidazole compounds as c-Kit inhibitors
JP2022548095A (ja) 接着分解剤及びその使用方法
JP2016523270A5 (enExample)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
JP2020525522A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP2014513139A5 (enExample)
CN103124730A (zh) 杂环炔苯类化合物及其药用组合物和应用
JP2019532950A (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
JP2014513140A5 (enExample)
JP6419800B2 (ja) Ｎｍｄａ受容体活性の調節因子としてのチアゾロピリミジノン
AU2015335783B2 (en) Tricyclic atropisomer compounds
JP2016525135A5 (enExample)
JP2014525432A5 (enExample)
JP2008535903A5 (enExample)
JP2016505010A5 (enExample)
JP2018522852A5 (enExample)
EP3209651A1 (en) Carbazole derivatives
KR20180052702A (ko) Perk 억제제로서의 1-페닐피롤리딘-2-온 유도체
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
CA3258449A1 (en) INDAZOLE MACROCYCLES AND THEIR USE
JP2017525717A5 (enExample)
JP2014521609A5 (enExample)
JP2019512534A5 (enExample)